Researchers at Georgia State University have identified two modified metabolite-derived compounds, MLY2 and MLY8, that outperform their precursor molecule in experimental models of ulcerative colitis.
Researchers at Georgia State University have identified two experimental compounds that could provide a starting point for developing new treatments for ulcerative colitis, a chronic inflammatory bowel disease that remains difficult to manage in some patients.
The compounds, MLY2 and MLY8, demonstrated improved anti-inflammatory activity compared with their precursor molecule in preclinical experiments. Published in the International Journal of Molecular Sciences, the findings indicate that modifying metabolites produced during the body’s normal processing of compounds could offer an alternative route to discovering new anti-inflammatory drugs.
The researchers evaluated both compounds in mice with experimentally induced colitis and in laboratory-cultured colon tissue from patients with treatment-refractory ulcerative colitis. Although the results are encouraging, further research is needed before their therapeutic potential can be established.
Metabolites offer an alternative route to drug discovery
Ulcerative colitis causes chronic inflammation of the gastrointestinal tract and can lead to persistent symptoms and periods of relapse. Despite advances in treatment, some patients do not achieve sustained remission or lose their response to therapy over time, creating a need for additional treatment options.
Developing effective anti-inflammatory drugs that are safe and suitable for oral administration remains an important challenge.
The Georgia State University team, led by researchers at its Institute for Biomedical Sciences, explored whether compounds produced during phase II metabolism could provide useful starting points for drug development.
Phase II metabolism is associated with detoxification and the deactivation of compounds. However, new evidence suggests that some metabolites retain biological activity or develop improved pharmacological properties.
The researchers focused on M13, a previously identified metabolite of 6-shogaol, a compound associated with anti-inflammatory activity. M13 had demonstrated enhanced anti-inflammatory effects and improved biopharmaceutical properties compared with its parent compound.
Building on this finding, the team investigated whether selectively modifying the glutathione tripeptide component of M13 could improve its biological activity. The aim was to establish whether a naturally derived metabolic product could serve as a scaffold for medicinal chemistry optimisation.
Two compounds improve experimental outcomes
The researchers evaluated MLY2 and MLY8 in mice with dextran sulphate sodium-induced colitis, an experimental model commonly used to investigate intestinal inflammation.
Both compounds improved several measures of disease activity, including restoring colon length and reducing faecal lipocalin-2, a biomarker associated with intestinal inflammation.
The team also tested the compounds in cultured colon tissue samples from patients with treatment-refractory ulcerative colitis. In these experiments, MLY2 and MLY8 suppressed the production of inflammatory cytokines more effectively than M13.
These findings are particularly relevant because the human tissue experiments provide an opportunity to assess biological activity in material derived from patients whose disease has proved difficult to treat.
However, laboratory-cultured tissue does not reproduce the complexity of the human body. The results therefore do not establish whether the compounds would improve symptoms or induce remission in patients.
The researchers also conducted preliminary safety and tolerability studies, although further investigation will be needed to establish their suitability for clinical development.
Further work needed to establish therapeutic potential
The study highlights a potential opportunity for drug discovery by treating biologically active metabolites as starting points for further chemical modification rather than simply as products of metabolism.
“This work shows that modifying the chemical structure of a biologically active phase II metabolite can be a productive strategy for discovering new anti-inflammatory drug candidates,” said Chunhua Yang, a senior author and Research Assistant Professor at Georgia State University’s Institute for Biomedical Sciences. ”The findings provide a foundation for follow-up studies, suggesting that biologically active phase II metabolites may represent underutilised scaffolds for medicinal chemistry optimisation in inflammatory disease.”
The next stage will be to determine whether the compounds retain their activity in further preclinical studies and establish their safety, pharmacological properties and potential dosing requirements.
If subsequent research supports the findings, MLY2 and MLY8 could provide leads for developing new treatments for ulcerative colitis. For drug discovery researchers, the work also reinforces the potential value of exploring metabolic products as sources of new therapeutic candidates.
No comments yet